CSIMarket Company Name, Ticker, Industry, else..
 
Quince Therapeutics Inc   (NASDAQ: QNCX)
 
Price: $27.1500 $-0.02 -0.074%
Day's High: $27.530000686645508 Week Perf: -8.12 %
Day's Low: $ 26.62 30 Day Perf: -17.5 %
Volume (M): 5,514 52 Wk High: $ 45.50
Volume (M$): $ 0 52 Wk Avg: $15.47
Open: $27.17 52 Wk Low: $0.79



 Market Capitalization (Millions $) 167
 Shares Outstanding (Millions) 6
 Employees 38
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 78
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company files an Annual Report on Form 10-K that includes forward-looking statements regarding its future results of operations, financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, research and development costs, regulatory approvals, and management's plans and objectives for future operations. These statements are based on current expectations and projections and are subject to risks, uncertainties, and assumptions outlined in the Risk Factors section.


   Company Address: 611 Gateway Boulevard, South San Francisco, 94080 CA
   Company Phone Number: 910-5717   Stock Exchange / Ticker: NASDAQ QNCX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -0.3%    
BCRX        4.7% 
BDTX   -0.51%    
EXEL        1.11% 
GILD        3.46% 
MRNA        15.94% 
• View Complete Report
   



Business Update

Quince Therapeutics Unveils Advanced PK Modeling Study for Pioneering Ataxia-Telangiectasia Therapy with eDSP,

Published Fri, Sep 26 2025 3:46 AM UTC

Empowering Therapeutics: Quince Therapeutics’ Advanced PK Modeling Study for Ataxia-Telangiectasia Treatment In a promising stride towards developing biologically attuned therapies for rare diseases, Quince Therapeutics recently announced the publication of a significant study in CPT: Pharmacometrics & Systems Pharmacology. This study elucidates the outcomes of an advance...
Business Update

Innovation Amidst Volatility Quince Therapeutics Advances in Rare Disease Treatments and Fiscal Resilience in 2024,

Published Tue, Mar 25 2025 4:12 AM UTC

Unlocking Potential: Quince Therapeutics Fiscal Year 2024 Financial Results and Strategic Developments in Rare Disease Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX), a pioneering biotechnology enterprise headquartered in South San Francisco, is steadfastly advancing the therapeutic landscape for rare diseases by leveraging the intrinsic potential of patient biology....
Business Update

Quince Therapeutics Showcases Progress in Ataxia-Telangiectasia Treatment Safety Data and Fast Track Designation Hi...

Published Tue, Nov 12 2024 3:36 AM UTC

In a significant advancement for the field of pediatric neurology and rare disease therapeutics, Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology firm based in South San Francisco, has presented safety data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; NCT02770807) clinical trial at the 53rd Child Neurology Society (CNS) Ann...
Business Update

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDe...

Published Thu, Aug 15 2024 12:09 PM UTC

Quince Therapeutics Unveils Promising Data on EryDex Treatment for Ataxia-Telangiectasia and Reports Encouraging Financial Outlook In the realm of biotechnology, the quest for effective treatments for rare diseases remains one of the most formidable challenges. Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage company at the forefront of this endeavor, has recently ma...
Business Update

FDA Grants Fast Track Designation to Quince Therapeutics for EryDex System Targeting Ataxia-Telangiectasia ...

Published Mon, Jun 3 2024 11:38 AM UTC

South San Francisco, Calif. Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its innovative EryDex System. This decision aims to expedite the development and review of the EryDex System, specifically targeting patients suffering from Ataxia-Telangiectasia...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 11.3
Working Capital Ratio 11.82
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) 9.08

Per Share Current
Earnings (TTM) -162.31 $
Revenues (TTM) -
Cash Flow (TTM) 0.22 $
Cash 18.91 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) 2,060,342
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) 2.76 %

Management Effectiveness Current
Return On Assets (TTM) 88.46 %
Return On Investment (TTM) 117.85 %
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.